Last reviewed · How we verify
High-dose rifampicin
High-dose rifampicin inhibits bacterial RNA polymerase to suppress mycobacterial growth and modulate immune responses.
High-dose rifampicin inhibits bacterial RNA polymerase to suppress mycobacterial growth and modulate immune responses. Used for Tuberculosis (likely indication given Seoul National University Hospital context and high-dose formulation).
At a glance
| Generic name | High-dose rifampicin |
|---|---|
| Sponsor | Seoul National University Hospital |
| Drug class | Rifamycin antibiotic |
| Target | Bacterial RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Rifampicin is a well-established antibiotic that binds to bacterial RNA polymerase, blocking transcription in mycobacteria. At high doses, it may also have immunomodulatory effects that enhance host immune responses against intracellular pathogens. This combination of direct antimicrobial activity and immune enhancement is being investigated in phase 3 trials.
Approved indications
- Tuberculosis (likely indication given Seoul National University Hospital context and high-dose formulation)
Common side effects
- Hepatotoxicity
- Drug-drug interactions
- Gastrointestinal disturbance
- Rash
- Orange discoloration of body fluids
Key clinical trials
- A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet (PHASE1)
- Drug Interaction and Food Effect Study of CS0159 (PHASE1)
- Shorter and Safer Treatment Regimens for Latent TB (PHASE2, PHASE3)
- Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women (PHASE1)
- Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis (PHASE3)
- Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression (PHASE3)
- Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients (PHASE4)
- Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High-dose rifampicin CI brief — competitive landscape report
- High-dose rifampicin updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI